Back

Accurate de novo design of high-affinity protein binding macrocycles using deep learning

Rettie, S.; Juergens, D.; Adebomi, V.; Bueso, Y. F.; Zhao, Q.; Leveille, A.; Liu, A.; Bera, A.; Wilms, J.; Üffing, A.; Kang, A.; Brackenbrough, E.; Lamb, M.; Gerben, S.; Murray, A.; Levine, P.; Schneider, M.; Vasireddy, V.; Ovchinnikov, S.; Weiergräber, O.; Willbold, D.; Kritzer, J.; Mougous, J.; Baker, D.; DiMaio, F.; Bhardwaj, G.

2024-11-18 biochemistry
10.1101/2024.11.18.622547 bioRxiv
Show abstract

The development of macrocyclic binders to therapeutic proteins typically relies on large-scale screening methods that are resource-intensive and provide little control over binding mode. Despite considerable progress in physics-based methods for peptide design and deep-learning methods for protein design, there are currently no robust approaches for de novo design of protein-binding macrocycles. Here, we introduce RFpeptides, a denoising diffusion-based pipeline for designing macrocyclic peptide binders against protein targets of interest. We test 20 or fewer designed macrocycles against each of four diverse proteins and obtain medium to high-affinity binders against all selected targets. Designs against MCL1 and MDM2 demonstrate KD between 1-10 M, and the best anti-GABARAP macrocycle binds with a KD of 6 nM and a sub-nanomolar IC50 in vitro. For one of the targets, RbtA, we obtain a high-affinity binder with KD < 10 nM despite starting from the target sequence alone due to the lack of an experimentally determined target structure. X-ray structures determined for macrocycle-bound MCL1, GABARAP, and RbtA complexes match very closely with the computational design models, with three out of the four structures demonstrating Ca RMSD of less than 1.5 [A] to the design models. In contrast to library screening approaches for which determining binding mode can be a major bottleneck, the binding modes of RFpeptides-generated macrocycles are known by design, which should greatly facilitate downstream optimization. RFpeptides thus provides a powerful framework for rapid and custom design of macrocyclic peptides for diagnostic and therapeutic applications.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.